What is an accelerated share repurchase (ASR)?

An ASR is a structured repurchase program where a company purchases a large block of shares immediately from an investment bank, rather than gradually through open-market purchases over time. The investment bank then covers its position by sourcing shares from the market or the company's existing repurchase authorization. ASRs allow companies to complete major buybacks quickly and often at potentially favorable execution mechanics.

How many shares did Boston Scientific repurchase, and what was the total authorization?

Boston Scientific repurchased approximately 40 million shares under the $2 billion ASR program. The filing does not disclose the average price paid per share, only the total dollar amount and share quantity.

What impact does this buyback have on Boston Scientific's earnings per share?

Retiring 40 million shares reduces the company's share count, which mechanically increases EPS by spreading the same net income across fewer shares. For Q2 2026, the diluted share count declined to 1,474.8 million from 1,493.5 million in the prior year—a roughly 1.3% reduction that will provide ongoing EPS accretion absent changes in profitability.

Did Boston Scientific authorize a new repurchase program in this filing?

No. This filing reports the completion of a previously announced $2 billion ASR program. No new authorization or expansion of buyback capacity is disclosed in this earnings release.

How does this buyback fit into Boston Scientific's overall capital strategy?

The company deployed the $2 billion for share repurchase while simultaneously investing $1.5 billion in MiRus LLC for a 34% equity stake. This balanced approach reflects management's intent to return capital to shareholders while funding strategic acquisitions and innovation in high-priority therapeutic areas.

What execution mechanism was used for this repurchase?

Boston Scientific used an accelerated share repurchase (ASR) mechanism, which is a negotiated block purchase typically executed with an investment bank. ASRs contrast with Rule 10b-18 open-market purchases, which occur gradually in the secondary market over time.

BSX 8-K Filed 2026-07-29 Execution disclosure

Boston Scientific completed $2B accelerated share repurchase, bought back 40M shares

Medical-device maker finishes previously announced ASR program in Q2 2026 as part of capital allocation strategy.

Shares repurchased40.0M

MechanismAccelerated Share Repurchase

What the filing says

Boston Scientific Corporation announced in its second-quarter 2026 earnings release that it has completed a previously announced $2 billion accelerated share repurchase (ASR) program, repurchasing approximately 40 million shares during the period.

The ASR execution was conducted under an accelerated share repurchase mechanism, which typically allows companies to purchase shares in a single lump transaction rather than through open-market purchases over time. The completion of this program was disclosed as part of Boston Scientific's quarterly financial results filed on July 29, 2026.

The repurchase activity reduced the company's diluted weighted-average share count from 1,493.5 million shares in the comparable 2025 period to 1,474.8 million shares in Q2 2026, a decrease of approximately 1.3% year-over-year. The buyback was part of the company's broader capital allocation strategy alongside investments in innovation, acquisitions, and operations.

Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares. — BOSTON SCIENTIFIC CORP 8-K filing · View on SEC EDGAR →

What this means

Boston Scientific's completion of its $2 billion ASR marks the fulfillment of a capital-return commitment announced previously. The 40 million shares repurchased represent roughly 2.7% of the diluted share count from the prior-year period, a material reduction that will support earnings-per-share accretion going forward, absent any change in net income. The buyback occurred during a period of solid operational performance—Q2 reported 7.5% revenue growth on a reported basis—and alongside a $1.5 billion investment in MiRus LLC, demonstrating the company's balanced approach to deploying capital for both shareholder returns and strategic growth initiatives.

Frequently asked questions

What is an accelerated share repurchase (ASR)?: An ASR is a structured repurchase program where a company purchases a large block of shares immediately from an investment bank, rather than gradually through open-market purchases over time. The investment bank then covers its position by sourcing shares from the market or the company's existing repurchase authorization. ASRs allow companies to complete major buybacks quickly and often at potentially favorable execution mechanics.
How many shares did Boston Scientific repurchase, and what was the total authorization?: Boston Scientific repurchased approximately 40 million shares under the $2 billion ASR program. The filing does not disclose the average price paid per share, only the total dollar amount and share quantity.
What impact does this buyback have on Boston Scientific's earnings per share?: Retiring 40 million shares reduces the company's share count, which mechanically increases EPS by spreading the same net income across fewer shares. For Q2 2026, the diluted share count declined to 1,474.8 million from 1,493.5 million in the prior year—a roughly 1.3% reduction that will provide ongoing EPS accretion absent changes in profitability.
Did Boston Scientific authorize a new repurchase program in this filing?: No. This filing reports the completion of a previously announced $2 billion ASR program. No new authorization or expansion of buyback capacity is disclosed in this earnings release.
How does this buyback fit into Boston Scientific's overall capital strategy?: The company deployed the $2 billion for share repurchase while simultaneously investing $1.5 billion in MiRus LLC for a 34% equity stake. This balanced approach reflects management's intent to return capital to shareholders while funding strategic acquisitions and innovation in high-priority therapeutic areas.
What execution mechanism was used for this repurchase?: Boston Scientific used an accelerated share repurchase (ASR) mechanism, which is a negotiated block purchase typically executed with an investment bank. ASRs contrast with Rule 10b-18 open-market purchases, which occur gradually in the secondary market over time.

execution accelerated-share-repurchase asr med-tech mega-cap q2-2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.